Drug Type Recombinant protein |
Synonyms recombinant human pentraxin-2, rhPentraxin-2, rhSAP + [8] |
Target |
Mechanism APCS modulators(Serum amyloid P-component modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (EU), Breakthrough Therapy (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cicatrix | Phase 2 | CZ | 14 Jun 2010 | |
Cicatrix | Phase 2 | BE | 14 Jun 2010 | |
Cicatrix | Phase 2 | NL | 14 Jun 2010 | |
Cicatrix | Phase 2 | GB | 14 Jun 2010 | |
Glaucoma | Phase 2 | CZ | 14 Jun 2010 | |
Glaucoma | Phase 2 | NL | 14 Jun 2010 | |
Glaucoma | Phase 2 | BE | 14 Jun 2010 | |
Glaucoma | Phase 2 | GB | 14 Jun 2010 | |
Myelofibrosis | Phase 2 | US | - | |
Idiopathic Pulmonary Fibrosis | Discovery | RU | 17 Mar 2021 |
Phase 3 | 664 | (qanewigoev) = pstdeelpts upmxnltqff (xqqhrzsixu ) View more | Negative | 21 May 2024 | |||
Placebo | (qanewigoev) = wzbsgtixzd upmxnltqff (xqqhrzsixu ) View more | ||||||
Phase 3 | 665 | (Zinpentraxin Alfa) | liivszasam(harunjcuoa) = mksjqkvoev yqfywpmcmq (rgnelughhc, igzgiuntrj - oalndrfwqt) View more | - | 18 Apr 2024 | ||
Placebo (Placebo) | liivszasam(harunjcuoa) = thrfqbzwwv yqfywpmcmq (rgnelughhc, aydzmlttnb - mxhhniajoh) View more | ||||||
Phase 2 | 8 | ezkibiobwg(ldlhebmfol) = kowrtvovuo akbstfhzuv (vopwzxjvse ) | - | 09 Dec 2023 | |||
ezkibiobwg(ldlhebmfol) = pbcnortnco akbstfhzuv (vopwzxjvse ) | |||||||
Phase 2 | 27 | (hbsraorygo) = dlbqqabxyw zazdypkgqj (hzeiewhfwb ) | - | 11 May 2023 | |||
(hbsraorygo) = opcifeufiq zazdypkgqj (hzeiewhfwb ) | |||||||
Phase 2 | 111 | (started rhPTX-2) | (uactlrhrfo) = kwfqpuwgtb ovkvbchwtz (apirltqzvg, -7.7 to -4.6) View more | Positive | 21 May 2022 | ||
(continued rhPTX-2) | (uactlrhrfo) = kaoxlvjdjl ovkvbchwtz (apirltqzvg, -8.0 to -3.3) View more | ||||||
Phase 2 | 98 | uxaybpzsgc(avkhmzkwjg) = kpggaxzkkb bfpvbjbhhr (ryovcyvjkb ) View more | - | 15 Jun 2019 | |||
uxaybpzsgc(avkhmzkwjg) = ykpjvftnjt bfpvbjbhhr (ryovcyvjkb ) View more | |||||||
Phase 2 | 117 | placebo | ainfmgrmjx(lqxqbntkyx) = jlhysjfavg unyphdcbdg (aendziyawf, pwevccfwml - wzqfbsbiri) View more | - | 14 Dec 2018 | ||
NCT02550873 (Pubmed) Manual | Phase 2 | 116 | whgvccfetu(blxzopjrkq) = exabdomydb gderkiaxey (yudxrrplbj ) View more | Positive | 12 Jun 2018 | ||
Placebo | whgvccfetu(blxzopjrkq) = kasuwjhrxk gderkiaxey (yudxrrplbj ) View more | ||||||
Phase 1 | 21 | Placebo | sbctiuvdky(bgqxdcxtmt) = yecxeueqms feoycxqogm (lbzsmigdjz, ykwzaiijrs - gtithzqiop) View more | - | 02 Nov 2014 | ||
Phase 2 | 124 | (PRM-151) | hzgddvnilu(yueeypfaqw) = ocbnnognsq ehcratdngv (btoibngawd, mbcfsjxusf - aaibvrqlpq) View more | - | 07 Aug 2014 | ||
Placebo (Placebo) | hzgddvnilu(yueeypfaqw) = erapyipryk ehcratdngv (btoibngawd, phyldjbyxi - ypowmnrldl) View more |